JP2020535832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535832A5 JP2020535832A5 JP2020519092A JP2020519092A JP2020535832A5 JP 2020535832 A5 JP2020535832 A5 JP 2020535832A5 JP 2020519092 A JP2020519092 A JP 2020519092A JP 2020519092 A JP2020519092 A JP 2020519092A JP 2020535832 A5 JP2020535832 A5 JP 2020535832A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tcr
- human
- antigen
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108091081548 Palindromic sequence Proteins 0.000 claims 1
- 239000004234 Yellow 2G Substances 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023220106A JP7747724B2 (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568339P | 2017-10-05 | 2017-10-05 | |
| US62/568,339 | 2017-10-05 | ||
| PCT/US2018/052432 WO2019070435A1 (en) | 2017-10-05 | 2018-09-24 | METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220106A Division JP7747724B2 (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535832A JP2020535832A (ja) | 2020-12-10 |
| JP2020535832A5 true JP2020535832A5 (enExample) | 2021-11-04 |
Family
ID=63841049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519092A Pending JP2020535832A (ja) | 2017-10-05 | 2018-09-24 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
| JP2023220106A Active JP7747724B2 (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220106A Active JP7747724B2 (ja) | 2017-10-05 | 2023-12-26 | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12227554B2 (enExample) |
| EP (2) | EP3692140B1 (enExample) |
| JP (2) | JP2020535832A (enExample) |
| KR (1) | KR102757789B1 (enExample) |
| CN (1) | CN111417720B (enExample) |
| AU (1) | AU2018345400B2 (enExample) |
| CA (1) | CA3077595A1 (enExample) |
| ES (1) | ES2960313T3 (enExample) |
| FI (1) | FI3692140T3 (enExample) |
| IL (1) | IL273698B2 (enExample) |
| MA (1) | MA50748A (enExample) |
| SG (1) | SG11202003112QA (enExample) |
| WO (1) | WO2019070435A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202874A1 (en) * | 2020-12-22 | 2022-06-30 | Carsten LINNEMANN | Peptide markers to track genetically engineered cells |
| US20240175047A1 (en) | 2021-02-25 | 2024-05-30 | Alaunos Therapeutics, Inc. | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof |
| US20250145950A1 (en) * | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| WO1997009419A1 (en) | 1995-09-05 | 1997-03-13 | The General Hospital Corporation | Monoclonal lymphocytes and methods of use |
| DE19905048A1 (de) | 1999-02-08 | 2000-08-10 | Gsf Forschungszentrum Umwelt | Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie |
| JP2003274960A (ja) * | 2000-02-03 | 2003-09-30 | Japan Science & Technology Corp | 可溶性ｔ細胞受容体タンパク質およびその作成方法 |
| JP2003276960A (ja) * | 2002-03-26 | 2003-10-02 | Mitsubishi Electric Corp | エレベーター制御システム |
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| US8772451B2 (en) * | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| WO2007131092A2 (en) * | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| WO2008089053A2 (en) | 2007-01-12 | 2008-07-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| WO2010088160A1 (en) | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| CN103124740B (zh) | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2835200T3 (es) | 2012-05-22 | 2021-06-22 | Us Health | Uso médico de células que comprenden receptores de células T anti-NY-ESO-1 |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| AU2014290288B2 (en) * | 2013-07-15 | 2018-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 E6 T cell receptors |
| CN106661098B (zh) * | 2014-05-29 | 2021-05-04 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e7的t细胞受体 |
| CA2963364A1 (en) * | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| EP3220928B1 (en) * | 2014-11-20 | 2022-10-05 | UMC Utrecht Holding B.V. | A method of obtaining a preparation enrichmed in engineered t cells with exogenous immune receptors |
| PL3223850T3 (pl) | 2014-11-26 | 2020-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t przeciwko zmutowanemu kras |
| EP3901169A1 (en) | 2015-09-15 | 2021-10-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing hla-cw8 restricted mutated kras |
| AU2017258745B2 (en) | 2016-04-26 | 2022-03-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-KK-LC-1 T cell receptors |
| LT3494133T (lt) | 2016-08-02 | 2022-12-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t ląstelės receptoriai |
-
2018
- 2018-09-24 AU AU2018345400A patent/AU2018345400B2/en active Active
- 2018-09-24 ES ES18786145T patent/ES2960313T3/es active Active
- 2018-09-24 US US16/652,948 patent/US12227554B2/en active Active
- 2018-09-24 IL IL273698A patent/IL273698B2/en unknown
- 2018-09-24 KR KR1020207012314A patent/KR102757789B1/ko active Active
- 2018-09-24 JP JP2020519092A patent/JP2020535832A/ja active Pending
- 2018-09-24 WO PCT/US2018/052432 patent/WO2019070435A1/en not_active Ceased
- 2018-09-24 FI FIEP18786145.5T patent/FI3692140T3/fi active
- 2018-09-24 CN CN201880076862.9A patent/CN111417720B/zh active Active
- 2018-09-24 MA MA050748A patent/MA50748A/fr unknown
- 2018-09-24 EP EP18786145.5A patent/EP3692140B1/en active Active
- 2018-09-24 EP EP23185846.5A patent/EP4269595A3/en active Pending
- 2018-09-24 CA CA3077595A patent/CA3077595A1/en active Pending
- 2018-09-24 SG SG11202003112QA patent/SG11202003112QA/en unknown
-
2023
- 2023-12-26 JP JP2023220106A patent/JP7747724B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huff et al. | The evolving role of CD8+ CD28− immunosenescent T cells in cancer immunology | |
| Palatella et al. | The dark side of Tregs during aging | |
| JP2016539929A5 (enExample) | ||
| JP2023164900A5 (enExample) | ||
| JP2019536461A5 (enExample) | ||
| JP2016509840A5 (enExample) | ||
| JP2020535832A5 (enExample) | ||
| JP2019516754A5 (enExample) | ||
| JP2004536615A5 (enExample) | ||
| JP2010505830A5 (enExample) | ||
| WO2016165632A1 (zh) | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 | |
| CN102911918A (zh) | 一种基因工程细胞及其在nk细胞扩增中的应用 | |
| JP2012505665A5 (enExample) | ||
| JP2011519869A5 (enExample) | ||
| JP2017508523A5 (enExample) | ||
| JP2013505296A5 (enExample) | ||
| JP2012508575A5 (enExample) | ||
| DE60332377D1 (de) | Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden | |
| Fang et al. | Adoptive cell therapy for T-cell malignancies | |
| Chen | Efficient gene editing in primary human T cells | |
| Kennedy et al. | Bone marrow fat and the decline of B lymphopoiesis in rabbits | |
| Piatakova et al. | Distinct responsiveness of tumor-associated macrophages to immunotherapy of tumors with different mechanisms of major histocompatibility complex class I downregulation | |
| JP2021503276A5 (enExample) | ||
| IL273698B1 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| MX2007006355A (es) | Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico. |